Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Rises 22 Percent to Lead BCW Index

Shares in Stratagene rose 22.4 percent over the five-day trading period ended Tuesday, far outgaining any of the other stocks that comprise the BCW Index. The gain is likely the result of investors believing that a recent sell off was unwarranted. Two weeks ago, the firm's shares dropped nearly 19 percent on news that a jury found the firm had willfully infringed patents held by Third Wave Technologies and ordered Stratagene to pay damages of $5.3 million (see BioCommerce Week 9/8/2005).

Waters and Beckman Coulter shared the largest declines for the week, finishing down 6.1 percent for the tracking period. Overall, the Index fell 2.2 percent.

In comparison, the Dow Jones Industrial Average declined 1.1 percent, the Nasdaq closed down 1.9 percent, and the Nasdaq Biotech Index also declined .5 percent.

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(September 20, 2005)
Last Price
(September 13, 2005)
% Change
Agilent
A
34.03
33.09
2.84
Applied Biosystems
ABI
23.07
23.13
-0.26
Beckman
BEC
54.06
57.58
-6.11
Bio-Rad
BIO
52.28
54.48
-4.04
Bruker
BRKR
4.33
4.56
-5.04
Fisher Scientific
FSH
63.01
63.49
-0.76
GE
GE
33.84
34.28
-1.28
Harvard Bio
HBIO
2.84
2.82
0.71
Invitrogen
IVGN
75.69
76.91
-1.59
Molecular Devices
MDCC
20.32
20.63
-1.50
PerkinElmer
PKI
19.71
20.39
-3.33
Qiagen
QGEN
13.17
13.1
0.53
Sigma
SIAL
60.34
62.51
-3.47
Stratagene
STGN
8.52
6.96
22.41
Thermo
TMO
30.13
30.76
-2.05
Waters
WAT
42.44
45.2
-6.11
Index Average
33.61
34.37
-2.20

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.